Publications by authors named "Ronjon Chakraverty"

Claim this Profile
A
Advancing the Integration of 'Basic/Fundamental' and Translational Cellular and Gene Therapy Science within the EBMT: Accelerating the Pathway to Progress.
Donal P McLornan, Mette D Hazenberg, Fabio Ciceri, Tobias Alexander, Emanuele Angelucci, Ronjon Chakraverty

Bone Marrow Transplant· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study.
Robert Zeiser, Domenico Russo, Ron Ram, Shahrukh K Hashmi, Ronjon Chakraverty

J Clin Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measure selection for an electronic patient-reported outcome (ePRO) system for CAR T-cell therapy patients: a modified Delphi consensus study.
Sarah E Hughes, Foram Khatsuria, Christel McMullan, Karen L Shaw, Anita Walker, Ronjon Chakraverty

EClinicalMedicine· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicentre adaptive randomised trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin versus calcineurin inhibitor-based or sirolimus-based post-transplant cyclophosphamide (Methods of T cell Depletion, MoTD trial).
Ronjon Chakraverty, Emma Kempshall, Fiona Dignan, Adrian Bloor, Matthew Collin

BMJ Open· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How Important Is Unrelated Donor Human Leukocyte Antigen Disparity in the Post-Transplant Cyclophosphamide Era?
Ronjon Chakraverty

J Clin Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies.
Foram Khatsuria, Christel McMullan, Olalekan Lee Aiyegbusi, Karen L Shaw, Roshina Iqbal, Ronjon Chakraverty

Lancet Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrating patient and public involvement and engagement in translational medicine.
Karen L Shaw, Melanie J Calvert, Persephone Borrow, Evelyn Chakera, Ronjon Chakraverty

Lancet· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive Performance of Cardiovascular Risk Scores in Cancer Survivors From the UK Biobank.
Celeste McCracken, Dorina-Gabriela Condurache, Liliana Szabo, Hussein Elghazaly, Fiona M Walter, Ronjon Chakraverty

JACC CardioOncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The road to refractory graft-versus-host disease is paved with good intentions.
Daniel North, Ronjon Chakraverty

J Clin Invest· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ALL-RIC trial protocol: a comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in complete remission.
David I Marks, Anna Castleton, Eduardo Olavarria, Maria Gilleece, Adele Fielding, Ronjon Chakraverty

BMJ Open· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic stem cell transplantation compared to conservative management in adults with inborn errors of immunity.
Morgane Cheminant, Thomas A Fox, Mickael Alligon, Olivier Bouaziz, Bénédicte Neven, Ronjon Chakraverty

Blood· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party.
Johannes Schetelig, Patrice Chevallier, Michel van Gelder, Jennifer Hoek, Olivier Hermine, Ronjon Chakraverty

Bone Marrow Transplant· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Graft-versus-host disease: a disorder of tissue regeneration and repair.
Ronjon Chakraverty, Takanori Teshima

Blood· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Natural History of Epstein-Barr Virus Replication and Viral Load Dynamics after Alemtuzumab-Based Allogeneic Stem Cell Transplantation.
Maria A V Marzolini, Andrew J Wilson, Emilie Sanchez, Ben Carpenter, Ronjon Chakraverty

Transplant Cell Ther· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.
Robert Zeiser, Nicola Polverelli, Ron Ram, Shahrukh K Hashmi, Ronjon Chakraverty

N Engl J Med· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party.
Johannes Schetelig, Patrice Chevallier, Michel van Gelder, Jennifer Hoek, Olivier Hermine, Ronjon Chakraverty

Bone Marrow Transplant· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Graft Versus Leukemia: Current Status and Future Perspectives.
Aideen T O'Neill, Ronjon Chakraverty

J Clin Oncol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of recovery following allogeneic CD34+-selected cell infusion without conditioning to correct poor graft function.
Maria M Cuadrado, Richard M Szydlo, Mike Watts, Nishil Patel, Hanna Renshaw, Ronjon Chakraverty

Haematologica· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Obese Liver Environment Mediates Conversion of NK Cells to a Less Cytotoxic ILC1-Like Phenotype.
Antonia O Cuff, Francesca Sillito, Simone Dertschnig, Andrew Hall, Tu Vinh Luong, Ronjon Chakraverty

Front Immunol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Graft-versus-host disease reduces lymph node display of tissue-restricted self-antigens and promotes autoimmunity.
Simone Dertschnig, Pamela Evans, Pedro Santos E Sousa, Teresa Manzo, Ivana R Ferrer, Ronjon Chakraverty

J Clin Invest· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative analysis of melphalan versus busulphan T-cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemia.
Rob S Sellar, Varun Mehra, Thomas A Fox, Andrew Grigg, Austin Kulasekararaj, Ronjon Chakraverty

Br J Haematol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A wave of monocytes is recruited to replenish the long-term Langerhans cell network after immune injury.
Ivana R Ferrer, Heather C West, Stephen Henderson, Dmitry S Ushakov, Pedro Santos E Sousa, Ronjon Chakraverty

Sci Immunol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unraveling the Mechanisms of Cutaneous Graft-Versus-Host Disease.
Pedro Santos E Sousa, Clare L Bennett, Ronjon Chakraverty

Front Immunol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.
Nimitha R Mathew, Francis Baumgartner, Lukas Braun, David O'Sullivan, Simone Thomas, Ronjon Chakraverty

Nat Med· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peripheral tissues reprogram CD8+ T cells for pathogenicity during graft-versus-host disease.
Pedro Santos E Sousa, Séverine Ciré, Thomas Conlan, Laura Jardine, Claire Tkacz, Ronjon Chakraverty

JCI Insight· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis